Semler Scientific (SMLR) to Release Earnings on Monday

Semler Scientific (NASDAQ:SMLR) is expected to be announcing its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect the company to announce earnings of ($0.1450) per share and revenue of $7.8650 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Monday, November 3, 2025 at 4:30 PM ET.

Semler Scientific (NASDAQ:SMLR) last announced its quarterly earnings data on Monday, August 4th. The company reported $5.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $5.31. The company had revenue of $8.22 million during the quarter, compared to analysts’ expectations of $8.10 million. Semler Scientific had a net margin of 86.20% and a return on equity of 43.84%.

Semler Scientific Stock Up 7.5%

SMLR stock opened at $26.46 on Friday. The company has a current ratio of 0.60, a quick ratio of 0.58 and a debt-to-equity ratio of 0.25. The firm has a 50-day moving average of $28.18 and a two-hundred day moving average of $33.74. Semler Scientific has a 12 month low of $21.84 and a 12 month high of $81.56. The company has a market cap of $400.60 million, a price-to-earnings ratio of 10.89 and a beta of 1.41.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Benchmark cut their price target on Semler Scientific from $101.00 to $86.00 and set a “buy” rating for the company in a report on Tuesday, September 23rd. Cantor Fitzgerald cut their target price on Semler Scientific from $61.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday, August 6th. Maxim Group lowered their price target on shares of Semler Scientific from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Friday, September 19th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Semler Scientific in a research report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Semler Scientific has an average rating of “Moderate Buy” and an average price target of $74.25.

Hedge Funds Weigh In On Semler Scientific

Institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Semler Scientific by 15.6% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,582 shares of the company’s stock worth $178,000 after purchasing an additional 617 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Semler Scientific by 23.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,143 shares of the company’s stock worth $160,000 after buying an additional 776 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Semler Scientific by 354.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,819 shares of the company’s stock worth $70,000 after buying an additional 1,419 shares in the last quarter. Nomura Holdings Inc. lifted its holdings in Semler Scientific by 5.8% during the 2nd quarter. Nomura Holdings Inc. now owns 37,824 shares of the company’s stock worth $1,465,000 after buying an additional 2,062 shares in the last quarter. Finally, Invesco Ltd. boosted its position in Semler Scientific by 24.4% in the 2nd quarter. Invesco Ltd. now owns 12,077 shares of the company’s stock valued at $468,000 after buying an additional 2,372 shares during the period. 49.37% of the stock is owned by institutional investors and hedge funds.

Semler Scientific Company Profile

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition.